Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients

Shu Huey Chen, Der Cherng Liang, Hung Ching Lin, Shu Yun Cheng, Lee Jen Chen, Hsi Che Liu

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Deferoxamine is a chelating agent that has extended the life expectancy of patients with thalassemia. In the 1980s, many investigators reported otologic and visual toxicity caused by deferoxamine. In July 1999 and 2 years later, the authors performed audiologic and ophthalmologic assessments in 30 transfusion-dependent patients receiving deferoxamine therapy (40-50 mg/kg per dose, subcutaneously for 8-10 hours, 4-7 days per week). In 1999, six patients (20%) had deferoxamine-related hearing impairment (>25 dB), all at high frequencies. Because the authors believed the benefits of chelation therapy outweighed the risk of ototoxicity, the dose of deferoxamine was not reduced. Two years later, the hearing impairment had not progressed in any of the patients. There was no association between ototoxicity and ferritin level. No patients had abnormalities of visual acuity or funduscopy in either 1999 or 2001. Based on this experience, deferoxamine at doses lower than 50 mg/kg/d was safe for the eyes and slightly toxic to the ears. The ototoxicity probably relates to individual susceptibility. Regular monitoring of auditory function and close follow-up of abnormal findings are recommended. According to this limited experience, reducing the dose or withdrawing deferoxamine might not be necessary if the hearing loss is stable in the face of ferritin levels above 2,000 ng/mL. Because of the relatively small patient numbers, more data are needed to confirm these conclusions.

Original languageEnglish
Pages (from-to)651-653
Number of pages3
JournalJournal of Pediatric Hematology/Oncology
Volume27
Issue number12
DOIs
Publication statusPublished - Dec 2005
Externally publishedYes

Fingerprint

Deferoxamine
Hearing Loss
Ferritins
Therapeutics
Chelation Therapy
Thalassemia
Poisons
Chelating Agents
Life Expectancy
Visual Acuity
Ear
Research Personnel

Keywords

  • Deferoxamine
  • Ototoxicity
  • Thalassemia
  • Visual toxicity

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. / Chen, Shu Huey; Liang, Der Cherng; Lin, Hung Ching; Cheng, Shu Yun; Chen, Lee Jen; Liu, Hsi Che.

In: Journal of Pediatric Hematology/Oncology, Vol. 27, No. 12, 12.2005, p. 651-653.

Research output: Contribution to journalArticle

Chen, Shu Huey ; Liang, Der Cherng ; Lin, Hung Ching ; Cheng, Shu Yun ; Chen, Lee Jen ; Liu, Hsi Che. / Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. In: Journal of Pediatric Hematology/Oncology. 2005 ; Vol. 27, No. 12. pp. 651-653.
@article{2b1985dca7794cac9ca9274236a1ae31,
title = "Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients",
abstract = "Deferoxamine is a chelating agent that has extended the life expectancy of patients with thalassemia. In the 1980s, many investigators reported otologic and visual toxicity caused by deferoxamine. In July 1999 and 2 years later, the authors performed audiologic and ophthalmologic assessments in 30 transfusion-dependent patients receiving deferoxamine therapy (40-50 mg/kg per dose, subcutaneously for 8-10 hours, 4-7 days per week). In 1999, six patients (20{\%}) had deferoxamine-related hearing impairment (>25 dB), all at high frequencies. Because the authors believed the benefits of chelation therapy outweighed the risk of ototoxicity, the dose of deferoxamine was not reduced. Two years later, the hearing impairment had not progressed in any of the patients. There was no association between ototoxicity and ferritin level. No patients had abnormalities of visual acuity or funduscopy in either 1999 or 2001. Based on this experience, deferoxamine at doses lower than 50 mg/kg/d was safe for the eyes and slightly toxic to the ears. The ototoxicity probably relates to individual susceptibility. Regular monitoring of auditory function and close follow-up of abnormal findings are recommended. According to this limited experience, reducing the dose or withdrawing deferoxamine might not be necessary if the hearing loss is stable in the face of ferritin levels above 2,000 ng/mL. Because of the relatively small patient numbers, more data are needed to confirm these conclusions.",
keywords = "Deferoxamine, Ototoxicity, Thalassemia, Visual toxicity",
author = "Chen, {Shu Huey} and Liang, {Der Cherng} and Lin, {Hung Ching} and Cheng, {Shu Yun} and Chen, {Lee Jen} and Liu, {Hsi Che}",
year = "2005",
month = "12",
doi = "10.1097/01.mph.0000194019.95096.b6",
language = "English",
volume = "27",
pages = "651--653",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients

AU - Chen, Shu Huey

AU - Liang, Der Cherng

AU - Lin, Hung Ching

AU - Cheng, Shu Yun

AU - Chen, Lee Jen

AU - Liu, Hsi Che

PY - 2005/12

Y1 - 2005/12

N2 - Deferoxamine is a chelating agent that has extended the life expectancy of patients with thalassemia. In the 1980s, many investigators reported otologic and visual toxicity caused by deferoxamine. In July 1999 and 2 years later, the authors performed audiologic and ophthalmologic assessments in 30 transfusion-dependent patients receiving deferoxamine therapy (40-50 mg/kg per dose, subcutaneously for 8-10 hours, 4-7 days per week). In 1999, six patients (20%) had deferoxamine-related hearing impairment (>25 dB), all at high frequencies. Because the authors believed the benefits of chelation therapy outweighed the risk of ototoxicity, the dose of deferoxamine was not reduced. Two years later, the hearing impairment had not progressed in any of the patients. There was no association between ototoxicity and ferritin level. No patients had abnormalities of visual acuity or funduscopy in either 1999 or 2001. Based on this experience, deferoxamine at doses lower than 50 mg/kg/d was safe for the eyes and slightly toxic to the ears. The ototoxicity probably relates to individual susceptibility. Regular monitoring of auditory function and close follow-up of abnormal findings are recommended. According to this limited experience, reducing the dose or withdrawing deferoxamine might not be necessary if the hearing loss is stable in the face of ferritin levels above 2,000 ng/mL. Because of the relatively small patient numbers, more data are needed to confirm these conclusions.

AB - Deferoxamine is a chelating agent that has extended the life expectancy of patients with thalassemia. In the 1980s, many investigators reported otologic and visual toxicity caused by deferoxamine. In July 1999 and 2 years later, the authors performed audiologic and ophthalmologic assessments in 30 transfusion-dependent patients receiving deferoxamine therapy (40-50 mg/kg per dose, subcutaneously for 8-10 hours, 4-7 days per week). In 1999, six patients (20%) had deferoxamine-related hearing impairment (>25 dB), all at high frequencies. Because the authors believed the benefits of chelation therapy outweighed the risk of ototoxicity, the dose of deferoxamine was not reduced. Two years later, the hearing impairment had not progressed in any of the patients. There was no association between ototoxicity and ferritin level. No patients had abnormalities of visual acuity or funduscopy in either 1999 or 2001. Based on this experience, deferoxamine at doses lower than 50 mg/kg/d was safe for the eyes and slightly toxic to the ears. The ototoxicity probably relates to individual susceptibility. Regular monitoring of auditory function and close follow-up of abnormal findings are recommended. According to this limited experience, reducing the dose or withdrawing deferoxamine might not be necessary if the hearing loss is stable in the face of ferritin levels above 2,000 ng/mL. Because of the relatively small patient numbers, more data are needed to confirm these conclusions.

KW - Deferoxamine

KW - Ototoxicity

KW - Thalassemia

KW - Visual toxicity

UR - http://www.scopus.com/inward/record.url?scp=29144466570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144466570&partnerID=8YFLogxK

U2 - 10.1097/01.mph.0000194019.95096.b6

DO - 10.1097/01.mph.0000194019.95096.b6

M3 - Article

VL - 27

SP - 651

EP - 653

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 12

ER -